English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 August 2018, 18:35 HKT/SGT
Share:
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.


Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
International Jatiluhur Jazz Festival 2019 draws thousands to the green of Jatiluhur Dam  
Dec 7, 2019 21:00 HKT/SGT
TransCanna Revenue Increases 90% Month over Month and Expands Facilities  
Dec 7, 2019 10:00 HKT/SGT
PBOC Issues 2020 Commemorative Coins for Year of the Rat  
Dec 7, 2019 09:30 HKT/SGT
Close to 1,500 e-tailers join Asian E-tailing Summit  
Dec 6, 2019 21:00 HKT/SGT
TOYOTA GAZOO Racing Back in Bahrain  
Dec 6, 2019 20:10 HKT/SGT
Xinyi Glass Garners "Enterprise Award" at "DHL/SCMP Hong Kong Business Awards 2019"   
Dec 6, 2019 19:25 HKT/SGT
SmartBiz Expo and Franchising Show close today  
Dec 6, 2019 19:00 HKT/SGT
Hitachi to Provide CNAO with Proton Therapy System   
Dec 6, 2019 18:16 HKT/SGT
First Trenitalia Chooses Hitachi Rail to Build New Intercity Trains for Avanti West Coast  
Dec 6, 2019 18:02 HKT/SGT
Fujitsu Launches SAP Solution to Support Mass Customization in Engineer-to-Order Production  
Dec 6, 2019 17:20 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575